Semler Scientific Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Semler Scientific te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Aug 2024

Recente toekomstige groei-updates

Recent updates

Semler Scientific, Inc. (NASDAQ:SMLR) Held Back By Insufficient Growth Even After Shares Climb 27%

Nov 02

Earnings Troubles May Signal Larger Issues for Semler Scientific (NASDAQ:SMLR) Shareholders

Aug 14

The Market Doesn't Like What It Sees From Semler Scientific, Inc.'s (NASDAQ:SMLR) Earnings Yet

Jul 18

We Ran A Stock Scan For Earnings Growth And Semler Scientific (NASDAQ:SMLR) Passed With Ease

May 08

Things Look Grim For Semler Scientific, Inc. (NASDAQ:SMLR) After Today's Downgrade

Mar 08

Semler Scientific: Why I'm Buying

Mar 05

Should You Investigate Semler Scientific, Inc. (NASDAQ:SMLR) At US$52.64?

Mar 02

Semler's Unique Business Model Is Fueling Profitable Growth

Feb 23

Better Price For Semler Is Likely

Jan 05

Semler Scientific's (NASDAQ:SMLR) Earnings Are Weaker Than They Seem

Nov 12

It Looks Like The CEO Of Semler Scientific, Inc. (NASDAQ:SMLR) May Be Underpaid Compared To Peers

Oct 15

Semler Scientific: Rapidly Growing Medical Device Company

Oct 14

There's Reason For Concern Over Semler Scientific, Inc.'s (NASDAQ:SMLR) Massive 28% Price Jump

Oct 14

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Semler Scientific onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:SMLR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2024	56	11	N/A	N/A	1
9/30/2024	59	16	-47	21	N/A
6/30/2024	62	16	-40	20	N/A
3/31/2024	66	22	26	26	N/A
12/31/2023	68	21	21	21	N/A
9/30/2023	67	20	17	19	N/A
6/30/2023	65	18	20	22	N/A
3/31/2023	61	16	14	17	N/A
12/31/2022	57	14	15	17	N/A
9/30/2022	54	13	16	17	N/A
6/30/2022	54	13	16	17	N/A
3/31/2022	54	16	12	13	N/A
12/31/2021	53	17	15	16	N/A
9/30/2021	54	21	19	20	N/A
6/30/2021	50	22	15	16	N/A
3/31/2021	42	16	15	16	N/A
12/31/2020	39	14	14	15	N/A
9/30/2020	36	11	12	13	N/A
6/30/2020	34	14	13	14	N/A
3/31/2020	35	16	13	15	N/A
12/31/2019	33	15	11	13	N/A
9/30/2019	30	14	10	11	N/A
6/30/2019	26	7	6	8	N/A
3/31/2019	24	6	6	7	N/A
12/31/2018	21	5	4	5	N/A
9/30/2018	20	4	2	3	N/A
6/30/2018	18	2	N/A	2	N/A
3/31/2018	15	0	N/A	1	N/A
12/31/2017	12	-2	N/A	1	N/A
9/30/2017	11	-2	N/A	0	N/A
6/30/2017	9	-2	N/A	0	N/A
3/31/2017	8	-2	N/A	-1	N/A
12/31/2016	7	-3	N/A	-2	N/A
9/30/2016	8	-7	N/A	-4	N/A
6/30/2016	7	-8	N/A	-3	N/A
3/31/2016	7	-8	N/A	-4	N/A
12/31/2015	7	-9	N/A	-4	N/A
9/30/2015	5	-5	N/A	-4	N/A
6/30/2015	4	-5	N/A	-4	N/A
3/31/2015	4	-5	N/A	-4	N/A
12/31/2014	4	-5	N/A	-4	N/A
9/30/2014	3	-4	N/A	-3	N/A
6/30/2014	3	-3	N/A	-2	N/A
3/31/2014	3	-2	N/A	-2	N/A
12/31/2013	2	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SMLR boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SMLR naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SMLR naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van SMLR naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van SMLR naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SMLR naar verwachting over 3 jaar hoog zal zijn

Semler Scientific Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 38% to US$40.00

Price target decreased to US$55.00

Semler Scientific Updates Financial Guidance for the Year Ending December 31, 2022

Semler Scientific, Inc. Provides Earnings Guidance for Second Half and Full Year Ended December 31, 2022

Semler Scientific, Inc. Provides Earnings Guidance for Second Half and Full Year Ended December 31, 2022

Consensus EPS estimates fall by 31%

Recent updates

Independent Chairman of the board recently bought US$1.9m worth of stock

CEO, President & Director exercised options and sold US$1.7m worth of stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Semler Scientific, Inc. (NASDAQ:SMLR) Held Back By Insufficient Growth Even After Shares Climb 27%

Investor sentiment improves as stock rises 22%

Semler Scientific, Inc. to Report Q3, 2024 Results on Nov 04, 2024

CEO, President & Director recently sold US$306k worth of stock

CEO, President & Director exercised options to buy US$2.0m worth of stock.

Semler Scientific, Inc., Annual General Meeting, Oct 04, 2024

Earnings Troubles May Signal Larger Issues for Semler Scientific (NASDAQ:SMLR) Shareholders

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$0.002 (vs US$0.88 in 2Q 2023)

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Semler Scientific, Inc. to Report Q2, 2024 Results on Aug 05, 2024

The Market Doesn't Like What It Sees From Semler Scientific, Inc.'s (NASDAQ:SMLR) Earnings Yet

Semler Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 36%

Investor sentiment improves as stock rises 38%

Investor sentiment deteriorates as stock falls 17%

New minor risk - Shareholder dilution

Price target decreased by 38% to US$40.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Ran A Stock Scan For Earnings Growth And Semler Scientific (NASDAQ:SMLR) Passed With Ease

Semler Scientific, Inc. to Report Q1, 2024 Results on May 07, 2024

Many Still Looking Away From Semler Scientific, Inc. (NASDAQ:SMLR)

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorates as stock falls 18%

Now 25% undervalued after recent price drop

Semler Scientific, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Is Now The Time To Put Semler Scientific (NASDAQ:SMLR) On Your Watchlist?

Investor sentiment improves as stock rises 16%

Estimating The Intrinsic Value Of Semler Scientific, Inc. (NASDAQ:SMLR)

Investor sentiment improves as stock rises 33%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Shareholder dilution

Semler Scientific, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Semler Scientific, Inc. Announces Steps Down of Abbie" Leibowitz as Class II Director

Investor sentiment improves as stock rises 15%

Semler Scientific, Inc., Annual General Meeting, Oct 19, 2023

Semler Scientific, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment improves as stock rises 24%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Does Semler Scientific, Inc.'s (NASDAQ:SMLR) Share Price Indicate?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Now 26% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Semler Scientific, Inc. Announces Major Clinical Study Using Semler's QuantaFlo® for Medicare Advantage Beneficiaries, Demonstrates that National, In-Home Screening for Peripheral Artery Disease (PAD) is Feasible

Investor sentiment improved over the past week

Calculating The Intrinsic Value Of Semler Scientific, Inc. (NASDAQ:SMLR)

Price target decreased to US$55.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Semler Scientific Updates Financial Guidance for the Year Ending December 31, 2022

Semler Scientific, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Semler Scientific, Inc., Annual General Meeting, Oct 20, 2022

Semler Scientific, Inc. Provides Earnings Guidance for Second Half and Full Year Ended December 31, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Semler Scientific, Inc. Provides Earnings Guidance for Second Half and Full Year Ended December 31, 2022

Semler Scientific: Growth, Profits, And Valuation Models Support A Buy

Investor sentiment improved over the past week

Semler Scientific, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 31%

Price target decreased to US$85.00

Semler Scientific: A Small Company Solving A Big Problem

Semler Scientific, Inc. to Report Q1, 2022 Results on May 02, 2022

Investor sentiment improved over the past week